Skip to main content
Quest Diagnostics

Maternal Red Blood Cell Alloimmunization Prevalence in the United States

Maternal Red Blood Cell Alloimmunization Prevalence in the United States

Authors: Sugrue RP, Moise KJ Jr, Federspiel JJ, Abels E, Louie JZ, Chen Z, Bare LA, Alagia DP 3rd, Kaufman HW

Citation: Blood Adv. 2024 Apr 25:bloodadvances.2023012241. doi: 10.1182/bloodadvances.2023012241. Online ahead of print.

Specialties: Infectious disease, Women's Health, OB, GYN, Hematology, Coagulation

Download key summary

Related content

Conference Presentation
Maternal Rates of Alloimmunization at Initiation of Pregnancy Care: Insights from a National Cohort
Test FAQ
Maternal Serum AFP
Publication
Editorial: Host-pathogen interactions during pregnancy: Effects on maternal health, pregnancy outcomes, and fetal development
Conference Presentation
Concordance of Phosphatidylserine/Prothrombin and APhLTM Antibodies Associated With Antiphospholipid Syndrome–Associated Pregnancy Morbidity
On-Demand Webinar
The Role of Adverse Pregnancy Outcomes in Heart Disease Prevention
Publication
Testing for Hepatitis C During Pregnancy Among Persons With Medicaid and Commercial Insurance: Cohort Study

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.